Guided Therapeutics (OTCMKTS:GTHP – Get Free Report) posted its quarterly earnings data on Monday. The company reported ($0.01) EPS for the quarter, Zacks reports. The business had revenue of $0.59 million for the quarter.
Guided Therapeutics Stock Performance
Guided Therapeutics stock remained flat at $0.23 during mid-day trading on Wednesday. The company had a trading volume of 11,296 shares, compared to its average volume of 16,659. The firm has a market cap of $21.27 million, a P/E ratio of -4.60 and a beta of 0.57. Guided Therapeutics has a 1 year low of $0.06 and a 1 year high of $0.54. The stock’s 50-day moving average is $0.34 and its 200 day moving average is $0.31.
Guided Therapeutics Company Profile
Guided Therapeutics, Inc is a medical device company focused on the development and commercialization of non‐invasive optical diagnostic platforms for women’s health. Its flagship product, the LuViva® Advanced Cervical Scan, combines hyperspectral and reflectance imaging to support the early detection of cervical epithelial abnormalities. By capturing tissue fluorescence and reflectance signatures in real time, LuViva is designed to augment traditional visual inspection methods and assist clinicians during colposcopic evaluations.
The company secured 510(k) clearance from the U.S.
Recommended Stories
Receive News & Ratings for Guided Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guided Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
